Back to News
Market Impact: 0.3
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst EstimatesCompany Fundamentals
Axsome Therapeutics reported a quarterly loss of $0.25 per share, narrower than the Zacks Consensus Estimate of a $0.69 loss. The loss also narrowed from $0.94 per share in the year-ago quarter.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
AXSM0.55
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead